JP2023543137A5 - - Google Patents
Info
- Publication number
- JP2023543137A5 JP2023543137A5 JP2023514105A JP2023514105A JP2023543137A5 JP 2023543137 A5 JP2023543137 A5 JP 2023543137A5 JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023543137 A5 JP2023543137 A5 JP 2023543137A5
- Authority
- JP
- Japan
- Prior art keywords
- dna template
- cell
- primary immune
- immune cells
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072080P | 2020-08-28 | 2020-08-28 | |
| US63/072,080 | 2020-08-28 | ||
| PCT/US2021/048066 WO2022047237A1 (en) | 2020-08-28 | 2021-08-27 | Engineered immune cells with priming receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543137A JP2023543137A (ja) | 2023-10-13 |
| JP2023543137A5 true JP2023543137A5 (enExample) | 2024-09-03 |
Family
ID=80352430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514105A Withdrawn JP2023543137A (ja) | 2020-08-28 | 2021-08-27 | プライミング受容体で操作された免疫細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230340409A1 (enExample) |
| EP (1) | EP4204575A4 (enExample) |
| JP (1) | JP2023543137A (enExample) |
| KR (1) | KR20230083275A (enExample) |
| CN (1) | CN116529364A (enExample) |
| AU (1) | AU2021334366A1 (enExample) |
| CA (1) | CA3191148A1 (enExample) |
| IL (1) | IL300994A (enExample) |
| MX (1) | MX2023002455A (enExample) |
| WO (1) | WO2022047237A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023004822A (es) * | 2020-10-26 | 2023-05-10 | Arsenal Biosciences Inc | Loci de puerto seguro. |
| CN119156398A (zh) * | 2022-04-20 | 2024-12-17 | 阿森纳生物科学公司 | 包含基因表达阻遏因子和/或合成途径激活因子和/或诱导型有效载荷的细胞 |
| CN119403825A (zh) * | 2022-05-17 | 2025-02-07 | 阿森纳生物科学公司 | 靶向psma和ca9的工程化受体的系统 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| IL322838A (en) * | 2023-03-13 | 2025-10-01 | Arsenal Biosciences Inc | Synthetic pathway operators |
| CN121674486A (zh) * | 2026-02-10 | 2026-03-17 | 潍坊吉涛医学科技有限公司 | 基于慢病毒载体的羊膜细胞永生化建系方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018175636A2 (en) * | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| SG11202004026QA (en) * | 2017-10-30 | 2020-05-28 | Pact Pharma Inc | Primary cell gene editing |
| KR20210039983A (ko) * | 2018-04-24 | 2021-04-12 | 리간달 인코포레이티드 | 게놈 편집을 위한 방법 및 조성물 |
| CN110184301B (zh) * | 2018-04-28 | 2023-02-24 | 辉大(上海)生物科技有限公司 | 通过Tild-CRISPR实现高效精确的靶向整合 |
| EP4034640A4 (en) * | 2019-09-23 | 2023-10-25 | Regents Of The University Of Minnesota | GENETICALLY EDITED IMMUNE CELLS AND THERAPY METHODS |
| MX2023004822A (es) * | 2020-10-26 | 2023-05-10 | Arsenal Biosciences Inc | Loci de puerto seguro. |
| JP2024512608A (ja) * | 2021-03-24 | 2024-03-19 | ジェネンテック， インコーポレイテッド | Ｔリンパ球における効率的なｔｃｒ遺伝子編集 |
| US20240352487A1 (en) * | 2021-08-11 | 2024-10-24 | UNIVERSITé LAVAL | Mtor -targeted modification and uses thereof |
-
2021
- 2021-08-27 MX MX2023002455A patent/MX2023002455A/es unknown
- 2021-08-27 IL IL300994A patent/IL300994A/en unknown
- 2021-08-27 CA CA3191148A patent/CA3191148A1/en active Pending
- 2021-08-27 KR KR1020237010538A patent/KR20230083275A/ko active Pending
- 2021-08-27 EP EP21862873.3A patent/EP4204575A4/en not_active Withdrawn
- 2021-08-27 JP JP2023514105A patent/JP2023543137A/ja not_active Withdrawn
- 2021-08-27 WO PCT/US2021/048066 patent/WO2022047237A1/en not_active Ceased
- 2021-08-27 AU AU2021334366A patent/AU2021334366A1/en active Pending
- 2021-08-27 CN CN202180073716.2A patent/CN116529364A/zh active Pending
-
2023
- 2023-02-27 US US18/114,981 patent/US20230340409A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543137A5 (enExample) | ||
| JP2024174943A5 (enExample) | ||
| JP2023100828A5 (enExample) | ||
| JP2020524998A5 (enExample) | ||
| JP2025013879A5 (enExample) | ||
| JP2018534950A5 (enExample) | ||
| JP2019115348A5 (enExample) | ||
| JP2016500262A5 (enExample) | ||
| JP2016521975A5 (enExample) | ||
| CN110577971B (zh) | CRISPR/Sa-SauriCas9基因编辑系统及其应用 | |
| US11998567B2 (en) | Engineered chimeric guide RNA and uses thereof | |
| WO2021082784A1 (zh) | 一种基于腺病毒的基因编辑方法 | |
| EP4175651A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| CN110499335B (zh) | CRISPR/SauriCas9基因编辑系统及其应用 | |
| CN110551761B (zh) | CRISPR/Sa-SepCas9基因编辑系统及其应用 | |
| JP2022527709A5 (enExample) | ||
| CN110551760A (zh) | 一种CRISPR/Sa-SeqCas9基因编辑系统和其应用 | |
| CN110551762B (zh) | CRISPR/ShaCas9基因编辑系统及其应用 | |
| CN110577969B (zh) | CRISPR/Sa-SlugCas9基因编辑系统及其应用 | |
| WO2025128722A2 (en) | Methods and compositions for genomic integration | |
| CN110499334A (zh) | CRISPR/SlugCas9基因编辑系统及其应用 | |
| CN110577970B (zh) | CRISPR/Sa-SlutCas9基因编辑系统及其应用 | |
| CN110577972B (zh) | CRISPR/Sa-ShaCas9基因编辑系统及其应用 | |
| CN110551763B (zh) | CRISPR/SlutCas9基因编辑系统及其应用 | |
| Epstein et al. | 119. Engineering a self-inactivating CRISPR system for AAV vectors |